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MyelosuppressionBased on the latest statistics on trends in cancer incidence and mortality worldwide, cancer burden is
growing at an alarming pace. Many anticancer drugs have been proved effective against cancer cells as
well as toxic to human tissues, which prevents sufﬁcient doses from being administered to obtain a com-
plete cure. In this paper we build an optimal control model to optimize the scheduling problem along one
cycle of chemotherapy treatment using a single anticancer drug etoposide (VP-16). In the model, three
mathematic models are adopted to mimic physiological response of body under chemotherapy: (i)
Pharmacokinetic model of anticancer drug; (ii) A two-compartment tumor growth dynamic model under
the inﬂuence of cell-cycle-speciﬁc anticancer drugs; and (iii) A semi-mechanistic model for myelosup-
pression. In this new integrated model clinically relevant objectives are proposed to gain a trade-off
between efﬁcacy and toxicity. Simulation results of clinical protocols are consistent with real-life clinical
data. Furthermore, we ﬁnd a new optimal drug regimen which can improve the efﬁcacy without the risk
of severe toxicity.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Cancer, also known as malignant tumor, is a group of diseases
involving abnormal cell growth with the potential to invade or
spread to other parts of the body. According to ‘World Cancer
Report 2014’ released by the International Agency for Research
on Cancer (IARC), in 2012 the worldwide burden of cancer rose
to an estimated 14 million new cases per year, and the ﬁgure is
expected to rise to 22 million annually within the next two dec-
ades. Over the same period, annual cancer deaths are predicted
to rise from an estimated 8.2 million to 13 million. As pointed
out by the Director of IARC, Dr. Christopher, ‘‘the rise of cancer
worldwide is a major obstacle to human development and
well-being. These new ﬁgures and projections send a strong signal
that immediate action is needed to confront this human disaster,
which touches every community worldwide, without exception’’.
Surgery, chemotherapy, radiotherapy, hormone therapy and
immunotherapy are the primary treatment options for cancer.
Since cancer cells can invade surrounding tissues and migrate to
the other parts of the body, chemotherapy is commonly employedas a systemic treatment by clinicians. Combining with surgery,
chemotherapy has been proven beneﬁcial in many different types
of cancer such as breast cancer, colorectal cancer, pancreatic
cancer, osteogenic sarcoma, testicular cancer, ovarian cancer, and
certain lung cancers. However, the effectiveness of chemotherapy
is often limited by toxicity to other tissues in the body due to the
interaction of the drug with normal cells. Clinicians need to put
forward a drug regimen to balance the treatment efﬁcacy with
the toxic side effects.
Randomized clinical trials are the standard method for the eval-
uation of efﬁcacy and toxicity of chemotherapy treatment plans.
The current standard of practice of treatment is based on empirical
evidence gathered from preclinical and clinical trials carried out
during the drug development process. However, given the limited
human and ﬁnancial resources for clinical trials, optimal protocols
cannot be determined empirically. To this end, mathematical mod-
eling provides a low-cost method for evaluating different strategies
more efﬁciently by describing the quantitative relations among
several factors [1].
The optimal control model (OCM) constructed by Martin et al.
[1,2] has been extensively used by the studies on chemotherapy
treatment optimization problem. Martin et al. [1,2] use the
Gompertz equation to describe tumor cell populations. Maximum
tolerated dose (MTD) and area under concentration (AUC) are indi-
cators of toxicity. A multiple characteristic time (MCT) constraint is
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rate in a speciﬁed time interval. More recently, Liang et al. [3–5]
modiﬁed the metabolism process of cumulative drug toxicity by
introducing a new parameter representing the elimination rate of
drug toxicity and applied several algorithms to the chemotherapy
scheduling problem.
The Gompertz model is capable of capturing clinically observed
tumor dynamics, but it cannot capture information regarding the
progression of cells through the individual phases of the
cell-cycle. Compartment models are developed to gain more
insight into cell behavior [6]. Based on the previous research,
Dua et al. [7] incorporate the cycle-speciﬁc chemotherapy effect
mechanism into the optimal control model (OCM), in which they
present two typical optimal control formulations that minimize
the ﬁnal tumor population subject to the constraints on toxicity
and drug resistance. A more complex description of the system
incorporates patient-speciﬁc parameters into their cell population
growth model, where an approximately optimal treatment plan is
found by applying simulated annealing algorithm [8].
Efforts have been made to shed light on interaction between
tumor and immune system. Villasana et al. [9,10] formulated the
action of a cycle-speciﬁc cytotoxic drug with the goal of maximiz-
ing cell kill fraction and minimizing normal cell killing and
designed a heuristic algorithm to ﬁnd optimal delivery schedules.
Furthermore, they incorporated a cytostatic drug which arrest cells
in a phase of their cycle. The problem of designing efﬁcient com-
bined chemotherapies is formulated as an optimal control problem
and tackled using three heuristic algorithms for real-parameter
optimization, namely, covariance matrix adaptation evolution
strategy, differential evolution, and particle swarm pattern search
method [11,12].
Research in the last ﬁve decades has led to the development of
Medical Decision Support (MDS) applications using a variety of
modeling techniques, for a diverse range of medical decision
problems, such as diagnostic decision support [13] and manage-
ment of hospital resources [14,15]. In this paper we focus on cancer
chemotherapy and dose schedule optimization using mathemati-
cal methods.
Although extensive efforts have been invested in the theoretical
investigation of chemotherapy control methods, we ﬁnd several
limitations to practical application. In most previous studies, the
toxicity of a treatment is measured both by maximum tolerated
dose and maximum drug exposure expressed as area under curve
(AUC). It relies on the assumption that today’s chemotherapy treat-
ments achieve the maximum efﬁcacy. However, we ﬁnd this
approach clinically unrealistic. In practical chemotherapy con-
stantly suffers from the inability to control the efﬁcacy-toxicity
balance. More importantly, AUC as an indicator of toxicity is argu-
able, since it induced unreasonable timing for the ﬁrst treatment in
the optimization problem in Martin et al.’s work [1,2]. Liang et al.
[3–5] attempted to ﬁx this by introducing a new parameter. While
Agur et al. [9] tried to model the interaction of drugs with normal
cells. Nevertheless, those methods cannot be applied directly
because parameters in their models are clinically unavailable. In
order to reduce the gap between theoretical investigation and
medical practice, we propose a more practical approach by inte-
grating a physiology-based model, i.e., the semi-mechanistic
model for myelosuppression proposed by Friberg et al. [16], into
the chemotherapy dose scheduling problem. This
semi-mechanistic model effectively captures the main physiologi-
cal processes and predicts the whole time course of leukopenia.
Based on this new model we are able to ﬁnd optimal drug regimen,
and identify new strategies to split the total drug dose so that tox-
icity will be reduced without compromising efﬁcacy.
The rest of the paper is organized as follows: Section 2 gives a
brief introduction on biomedical background and describes thepharmacokinetic model of VP-16, tumor growth dynamic model
and chemotherapy-induced myelosuppression model in detail.
Section 3 is the simulation results of different clinical protocols
and Section 4 works on optimizing dose regimens in cancer
chemotherapy. Conclusions and discussions are presented in
Section 5.
2. Problem formulation
2.1. Biomedical background
In cancer treatment, measurement of tumor growth is neces-
sary for preclinical and clinical assessment of efﬁcacy. To model
untreated tumor growth, exponential, Gompertz and logistic
growth models are commonly used but cell-cycle models provide
more insight into cell behavior. Cell cycle is a chain of phases that
both normal and cancer cells undergo from their birth to death. In
general, the cycle comprises of ﬁve stages which are G0, G1, S, G2
and M. G0 stands for resting phase. Cycling cell has four phases,
including the gap period (G1), the synthetic period (S), the second
gap period (G2), and mitosis (M). Usually, cancer drugs work by
damaging the RNA or DNA to halt division. Anticancer drugs that
are able to kill all cancer cells are called cell-cycle non-speciﬁc;
while drugs that only kill cancer cells when they are dividing are
called cell-cycle speciﬁc.
Since anticancer drugs attack both normal and cancer cells,
their usage often lead to severe side effects. Side effects of anti-
cancer chemotherapy include hematological toxicity, nausea, vom-
iting, diarrhea, fatigue, alopecia, and cardiac, neurological, and
renal toxicity. The main toxicity of most anticancer drugs is hema-
tological. Thus, the ability to anticipate hematological toxicity
could be of great value for optimizing treatment and predicting
complication for patients who undergo prolonged periods of
myelosuppression [17].
Etoposide (VP-16) is a cell-cycle speciﬁc anticancer drug that
has been widely used in chemotherapy treating childhood leuke-
mia, testicular tumors, Hodgkin’s disease, large cell lymphomas
and small cell lung cancer (SCLC). The activity of VP-16 is dose-
and schedule-dependent, and efﬁcacy might be improved mark-
edly with repeated drug administration. However, myelosuppres-
sion as the dose-limiting toxicity for VP-16 should be taken into
account when planning the chemotherapy regimen. The
chemotherapy treatment is given in cycles, attacking cancer cells
at their most sensitive periods, and allowing normal body cells
time to recover [18].
2.2. PK–PD model
Cancer progression in a patient undergoing chemotherapy is a
very complex process. Engineers have considered the development
of drug administration schedules for simulated cancer patients
constrained by pharmacokinetic (PK) and pharmacodynamic (PD)
models to meet the challenge [19] (see Fig. 1).2.2.1. Pharmacokinetic model
Pharmacokinetic models can include the distribution of drugs
by the circulatory system, the elimination of drug, and the amount
of drug present at the site of action. Systems of linear ordinary dif-
ferential equations (ODEs) are commonly used to describe the
dynamic relationship between the kinetic behavior of the drug
administered and corresponding concentration. Regarding VP-16,
a two-compartment PK model (as in Fig. 2) has the best ﬁt [20].
The mathematical models are as follow:
_Xc ¼ K21  Xp  ðK12 þ K10Þ  Xc þ X0 ð1Þ
IV Dose
Cancer
cells
Bone 
marrow
Toxicity Myelosuppression
Pharmacokinetics
Efficacy Anticancer effect
PlasmaPeripheral
Pharmacodynamics
Fig. 1. PK–PD relationships where PK models describe the distribution and
metabolism of the drug while PD models characterize the effects (which are
toxicity and efﬁcacy) of drugs on the organism (such as bone marrow and cancer
cells, respectively).
X0K12
K21
K10Xp Xc
Fig. 2. Two-compartment PK model.
Fig. 3. Unperturbed tumor growth.
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C ¼ Xc=Vc ð3Þ
where Xc and Xp represent the drug level in central and peripheral
compartment, respectively. Note that central compartment here is
plasma. K12 and K21 are transfer rates of drugs between compart-
ments, and K10 describes the total clearance rate of drug. X denotes
the dose of drug administered; Vc is the volume of central compart-
ment, and C denotes the drug concentration in plasma. Parameter
values are given in Table 1.
2.2.2. Tumor growth dynamic
There are a number of models that have been developed to
describe the tumor growth dynamic. Empirical models such as
exponential, Gompertz and logistic equations are most commonly
used. In particular, the Gompertz model is generally recognized as
the best ﬁt to describe the unperturbed growth of a population of
cancer cells. While the two-compartment model used in our study
is based upon an understanding of cell mechanisms. Fig. 3 is the
predicted tumor growth by compartment model and Gompertz
model without chemotherapy. Qualitative patterns are approxi-
mately similar.
However, there are certain limitations to adopting the
Gompertz model to represent cancer cell population under the
inﬂuence of chemotherapy, especially when anticancer drugs are
cell-cycle-speciﬁc. The Gompertz equation considers cancer cells
as homogeneous not only throughout their growth but also after
being perturbed by an anticancer drug. While forTable 1
Parameters used for PK model [20].
Parameter Value
K12 0.14/h
K21 0.06/h
K10 1.14 L/h
Vc 6 Lcell-cycle-speciﬁc drugs like etoposide, the agent only affect tumor
cells in certain phases. As a result, prediction of tumor growth from
Gompertz model may go against clinical facts when anticancer
drugs are cell-cycle-speciﬁc, as in the study of Iliadis and
Barbolosi [21]. In their work, the 1 day and 5 days regimens of eto-
poside have the equivalent effect on tumor fate at the end of treat-
ment cycle. While clinical trial conducted by Slevin et al. [22]
showed that even with the same total drug dose, differences in
response rates were dramatic.
The two-compartment model characterizing tumor cells as
cycling and resting (see Fig. 4) is helpful in understanding how
cell-cycle-speciﬁc anticancer drug works [6]. The cycling cells com-
partment represents cancer cells that are vulnerable to anticancer
drugs. Resting cells do not response to drugs directly, but are
affected by chemotherapy due to the interaction with cycling cells
compartment.
The model is based on ﬁve basic assumptions:
Assumption A: Tumor growth is a linear system, i.e. ﬁrst-order
kinetics;
Assumption B: Parameters are constant;
Assumption C: Do not take into account spatial or age effect;
Assumption D: Combine four cycling phases into one cycling
compartment;
Assumption E: Resting cells are not affected by the drugs.
The mathematical model is given by:
_X1 ¼ ða l gÞ  X1 þ b X2  gðtÞ  X1 ð4Þ
_X2 ¼ l X1  b X2 ð5Þ
In this model, X1 and X2 represent the cycling and resting cells,
respectively. a is the growth rate of cycling cells, l and b are the
mutation rates between two compartments. g is the motility rateResting 
Cells
Cycling 
Cells
Fig. 4. Tumor growth dynamic.
Table 2
Parameter used for tumor growth dynamic [6].
Parameter Value (day1)
a 0.5
l 0.218
g 0.477
b 0.05
Table 3
Parameters used for myelosuppression model [16].
Parameter Value
ktr 0.7680 day1
Circ0 5  109 L1
c 0.17
Slope 0.126 lM1
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Chemotherapy-efﬁcacy is represented by g(t), where g(t) = k1  C;
All parameters are constant and positive. We assume that there
is positive net growth rate (a > g), so that tumor will grow without
treatment. Detailed parameter values are shown in Table 2.
2.2.3. Pharmacodynamic model of toxicity
One component in optimizing cancer chemotherapy is to estab-
lish relationships between drug concentration and myelosuppres-
sion. Iliadis and Barbolosi [21] attempts to ﬁnd optimal drug
regimen which minimizes tumor at the end of the ﬁrst chemother-
apy cycle and minimizes toxicity by considering tumor and white
blood cells’ (WBC) responses to chemotherapy. The model consists
of ordinary and delay differential equations, where the peripheral
WBC counts are taken as having constant production and elimina-
tion, with a constant delay effect of chemotherapy. The constraints
they selected have certain clinical meanings, but this optimization
problem cannot be applied in the clinical setting because of its
simpliﬁcation of the underlying kinetics.
To accurately predict both the degree and duration of hemato-
logical toxicity, physiology-based models show great potential
with parameters that refer to actual processes and conditions. A
semi-mechanistic model (Fig. 5) in vogue is developed by Friberg
et al. [16] who describe chemotherapy-induced myelosuppression
through drug-speciﬁc parameters and system-related parameters.
This model has proven its worth by describing myelosuppression
after chemotherapy with docetaxel, paclitaxel, epirubicin–
docetaxel (ET), 5-ﬂuorouracil–epirubicin–cyclophosphamide (FEC),
topotecan, and etoposide [23,24]. Visual predictive checks showed
that the model described the data adequately [25]. Parameter
estimates were obtained from clinical data. The model was valid
for different drugs. In addition, consecutive courses and different
schedules of administration were also well characterized.
The semi-mechanistic model consists of ﬁve compartments.
Prol represents proliferating cells in the bone marrow. Three transit
compartments mimic the maturation chain of leukocyte and neu-
trophil. This chain delays the effects of chemotherapy toxicity as
cells propagate from the bone marrow to the observed circulating
white blood cells, which corresponds to Circ in this model. kprol
denotes the generation of new cells in Prol compartment. ktr allows
prediction of a time delay between administration and the
observed effect. Feedback mechanism describes the rebound of
cells.
The differential equations are presented as follows:
_Prol ¼ kprol  Prol ð1 EdrugÞ  ðCirc0=CircÞc  ktr  Prol ð6Þkcirc=ktr
ktrktrktrktr
kprol=ktr
Prol CircT T T
Fig. 5. Semi-mechanistic model for myelosuppression._T1 ¼ ktr  Prol ktr  T1 ð7Þ
_T2 ¼ ktr  T1  ktr  T2 ð8Þ
_T3 ¼ ktr  T2  ktr  T3 ð9Þ
_Circ ¼ ktr  T3  ktr  Circ ð10Þ
In which the hematological toxicity is Edrug, with
Edrug = Slope  C (see Table 3).
2.3. Clinically relevant objectives
Cancer chemotherapy is a systemic treatment, so the drug
would cause severe side effects if it is not administered appropri-
ately. The most commonly used restrictions in chemotherapy opti-
mization are maximum tolerated dose (MTD) and maximum drug
exposure which is measured by AUC. However, there are some
drawbacks concerning the use of AUC. First, AUC is a static mea-
surement, while medical decision making is a dynamic process.
Furthermore, the constraint on drug exposure evaluated by AUC
suggests delayed delivery of the bulk of doses which is clinically
unrealistic. The last but not the least, signiﬁcance of AUC with
regard to the toxicity effect is not always well deﬁned. It’s known
that myelosuppression is the dose limiting factor for many drugs.
Grades of myelosuppression relate to nadir of absolute neutrophil
counts (ANC). Therefore using models to predict neutrophil counts
has clinical potential in toxicity management. ANC serves as an
index for magnitude and duration of myelosuppression, and can
easily be obtained from a regular blood test. Noticing that ANC cor-
responds to Circ in the model.
To avoid severe bone marrow suppression, the absolute neu-
trophil counts should never descend below the level of clinical
leukopenia. This is expressed as below:
Circ  Circth ð11Þ
The main goal in cancer chemotherapy is to cure the patient,
and it is important to do so as efﬁciently as possible. Response rate
is a major prognostic factor in cancer. And it is measured by the
reduction of tumor volume according to WHO or RECIST standard.
Tumor volume can be obtained from CT scan. And tumor cell pop-
ulation is calculated as follows:
Tumor Weight ¼ Length ðmmÞ Width
2ðmm2Þ
2
 q ð12Þ
where tumor mass of 1 kg corresponds to tumor cell population of
1012. The objective is to achieve a higher response rate or less sur-
vival fraction of tumor cell population.
3. Clinical protocols and simulation results
3.1. Clinical administration protocol
Chemotherapy involves a course of several cycles of treatment.
A cycle may last for 3–4 weeks. A reason for having chemotherapy
as a course of treatment is that some of the cells that are resting
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ment when they are dividing.
The cycle of anticancer drug VP-16 was repeated at about
3-week intervals, so the treatment period was assumed to be
21 days. A wide range of doses and schedules of VP-16 are in
use. In patients with solid tumors, including SCLC, a high dose
scheme of 500 mg/m2 infused over 1 day, or lower doses, such as
100–125 mg/m2/day over 3–5 days are scheduled [22,26], while
others suggest prolonged schedule as superior [27]. In most regi-
mens VP-16 is administered in cycles, which are usually repeated
every 3–4 weeks.
First, simulation studies of clinical protocols are carried on to
validate the correctness of the established model. ODEs were
numerically solved by Runge–Kutta method. The protocols
adopted in our studied are listed as follows,Protocol 1: 500 mg/m2 infused over 1 dayFig. 6. Time course of tumor cells.[22]
Protocol 2: 100 mg/m2 for 5 days [22]
Protocol 3: 125 mg/m2 for 3 days [26]
Protocol 4: 25 mg/m2 over 21 days [27]3.2. Treatment efﬁcacy evaluation
Anticancer effects of different dose schedules are evaluated
after chemotherapy. Fig. 6 is the predicted time course of tumor
cells following different protocols in the ﬁrst treatment cycle. A
24 h infusion regimen (Protocol 1) results in the least tumor reduc-
tion. While the 21 days schedule yields signiﬁcant improvement in
antitumor effect, which suggests that a prolonged exposure to low
concentration of VP-16 may improve therapeutic ratio of this drug.
One possible explanation for this phenomenon is that a chronic
scheduling increased likelihood of exposing malignant cells to
VP-16 during sensitive periods of the cell cycle. It also indicates
that chemotherapy with VP-16 is schedule dependent.
The effectiveness of chemotherapy also depends on many fac-
tors such as the type and stage of cancer, as well as the general
condition of patients. Since VP-16 only affects cycling cells, we
studied the impact of proliferation index (PI) on response rates.Proliferation index represents initial fraction of cycling cells.
Therapeutic efﬁcacy is evaluated after 2 cycles of chemotherapy.
The predicted survival fractions are plotted for a range of values
of PI. Fig. 7 is the relationship between proliferation index and sur-
vival fraction of tumor cells after 2 cycles of treatment. It is clear
that prolonged administration performs better for patients with
lower PI. This may be the reason why small cell lung cancer has
higher response rate than breast cancer and non-small cell lung
cancer, noticing that SCLC has a much shorter doubling time.
When PI increases, short-term high-dose schedules have better
response. However, it’s known that approximately only 20% of the
cells are cycling. In addition, patients in Phases I/II clinical trials are
either in extensive stage or refractory, therefore PI is relatively low.
But theoretically speaking, when PI was 1, all tumor cells are
cycling. It is similar to cell-cycle non-speciﬁc chemotherapy sce-
nario, where intensive chemotherapy results in better therapeutic
efﬁcacy.
Impacts of different drug-sensitivity were also studied. Fig. 8 is
prediction for patients that are more sensitive to VP-16.
Respectively, Fig. 9 depicts the relationships between survival frac-
tion and PI with drug resistance. It is clear that prolonged low-doseFig. 7. Relationship between proliferation index and survival fraction.
Fig. 8. PI and SF with high drug-sensitivity.
Fig. 9. PI and SF with drug-resistance.
Fig. 11. Total area under concentration.
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ules show potential values when taking drug resistance into
account. Individual drug-sensitivity parameters can be estimated
using data from previous cycles. Adjustments on dose schedule
could be made accordingly.3.3. Toxicity management
Another important consideration for chemotherapy is toxicity
management. Since myelosuppression is the dose-limiting factor
for VP-16, accurate predictions of neutrophil counts during
chemotherapy could help in toxicity control. Fig. 10 is the time
courses of neutrophil counts during the ﬁrst cycle of chemotherapy
treatment. There is no signiﬁcant difference in ANC among
Protocols 1–3, which indicates similar toxicity. While the 21 days
(Protocol 4) schedule causes less risk of neutropenia. Fig. 11 is
the total area under concentration, which however, has failed to
predict chemotherapy-induced toxicity. Simulation results alsoFig. 10. Time courses of neutrophil counts.show that absolute neutrophil counts at nadir are around or above
2  109 L1. Patients do not experience neutropenia, which means
all protocols are conservative. It suggests that chemotherapy efﬁ-
cacy can be improved without the risk of severe toxicity by opti-
mizing dose schedules.4. Optimal drug regimen
Since chemotherapy using VP-16 is schedule-dependent and
simulation of clinical protocols indicates increasing of dose is
possible, it is necessary to ﬁnd the optimal drug regimen. An
optimization of the 5 days dose schedule is conducted. Nonlinear
programming and numerical integration techniques within
MATLAB were used to solve the optimal control problem.
A constraint was placed on the nadir of ANC during chemother-
apy to control drug-induced toxicity. Neutrophil counts of 1.5 
109 L1 and 1  109 L1 are the threshold values for grades 2 and
3 neutropenia, respectively. Several clinical studies suggest that a
grades 2–3 neutropenia increased patient survival compared to
milder or more severe toxicity [28–30]. Therefore, Circth in Eq.
(11) are 1.5  109 L1 and 1  109 L1, respectively. Two optimal
doses are obtained. Comparisons between standard dose and opti-
mal doses is presented in Fig. 12. Standard dose is rather conserva-
tive since patient does not experience any neutropenia, and has the
least antitumor effect as well. For both optimal doses, more tumor
cells are eliminated. 5  1010 more for optimal dose 1 and 3  1010
more for optimal dose 2 compared to standard dose. Meanwhile
maximum allowed toxicity was reached in both cases.
It is apparent that therapeutic efﬁcacy and drug-induced toxic-
ity are two conﬂicting objectives. Fig. 13 depicts the relationship
between the two objectives. ANC ranges of 1.5  109 L1–
1.9  109 L1, 1.0  109 L1–1.4  109 L1 and 0.5  109 L1–
0.9  109 L1 represent grades 1–3 clinical neutropenia. Grade 4
neutropenia is strictly prohibited. Decision could be made based
on individual conditions. For patients with better general condi-
tion, dose schedules in area t could be considered in order to kill
as much tumor cells as possible. Doses in area r are suitable for
palliative chemotherapy to improve quality of life. While dose
schedules in areas indicate balance between efﬁcacy and toxicity,
and are generally suggested.
Fig. 12. Comparisons of optimal regimens with standard dose.
Fig. 13. Relationship between response rate and ANC nadir.
26 J. Zhu et al. / Journal of Biomedical Informatics 57 (2015) 20–275. Conclusions and discussion
This paper addresses the chemotherapy dose scheduling as an
optimization problem. A two-compartment model was used to
describe the tumor growth which incorporated the cell cycle
dynamic. Semi-mechanistic PK–PD models were built to mimic
the metabolism process of drug-cell activities. This model is
physiology-based with parameters referring to actual processes
and conditions which greatly increases the likelihood of clinical
application. Simulation of clinical protocols is consistent with pub-
lished data which validates the correctness of model. Optimal drug
regimen suggests improvement could be achieved in chemother-
apy using etoposide (VP-16) with better drug administration.
Clinical relevant parameters and objectives are included.
Proliferation index, tumor volume and ANC baseline are clinical
parameters representing general conditions of patients. PI affectsresponse rates to different schedules. ANC baseline is a major con-
cern in toxicity management. Response rate and ANC data col-
lected during chemotherapy are crucial in estimating drug
sensitivity of individual patient. Adjustments could be made based
on data from previous courses. This model could be a useful tool to
support personalized chemotherapy decision making process.Conﬂict of interest
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